



Press Release

With 2 Argentinean acquisitions Ceva Santé Animale strengthens its activities in Latin America

Libourne, December 5, 2022 - Ceva Santé Animale (Ceva) announces the acquisition of the Argentinian companies Zoovet - specialized in the production and marketing of animal health products and Biotechnofe - a biotech start-up developing innovative products to be distributed by Zoovet.



These strategic acquisitions will give Ceva access to a state-of-the-art biotechnology campus based in Santa Fe, Argentina. With 200 experts and a tight collaboration with the prestigious university of the city mentioned above, this campus will strengthen Ceva's activities in Latin America to support pharmaceutical innovation, especially for ruminants.

As a result, Ceva will become the 5th largest player in Argentina, with 250 employees and an expected turnover of 35 million euros.

"At Ceva, our priority is to develop innovative and effective solutions for animal health and welfare. This strategic buyout will help us to increase our footprint in Latin America, one of the world's major animal protein producing regions. At Ceva, we are committed to providing solutions that help farmers to keep their animals healthy. This is the meaning of the work carried out by Zoovet and Biotechnofe, which has a proven track record as a biotechnology campus. Being innovative is not just about optimizing products, it's also about finding new ways to create a positive impact for our society and our planet." said Marc Prikazsky, President and CEO of Ceva Santé Animale.

This double acquisition echoes Ceva's vision "together beyond animal health" and will enable the company to accelerate its research work, particularly in biotechnology, to meet the needs and challenges of ruminant breeders.

For this strategic acquisition, Ceva chose family businesses that share common values around the One Health concept: *"At Zoovet and Biotechnofe we are committed to caring for people and animals. As at Ceva, we are convinced that both are intimately linked. We are strong advocates of the One Health concept. This is why, over the last few years, we have put all our energy into researching and developing pharmaceutical products to meet the needs and stakes of*

breeders to keep on feeding our planet in a qualitative and sustainable way. We are convinced that Ceva will continue this tradition and look forward to seeing the tangible positive impacts of it. stated Enrique Ariotti, founder and president of Zoovet and Biotechnofe

- END -

About Ceva Santé Animale:

Ceva Santé Animale is a French multinational veterinary pharmaceutical company created in 1999. Chaired by Dr. Marc Prikazsky, Ceva specializes in the research, development, production and marketing of pharmaceutical products and vaccines for livestock (ruminants, swine, poultry) and companion animals. Ceva is present in 110 countries and employs over 6300 people worldwide.

2021 turnover: €1.4 billion.

Website: <http://ceva.com>

About Zoovet SA:

It began in 1998 with the idea of providing veterinarians with products that effectively solve animal health problems at reasonable prices.

Today, 24 years later, Zoovet can ensure that the key to the success is the unique formulations and innovative combinations of active ingredients that the products offer.

The company has a distribution logistics that allows them to be where the client requires it in record time throughout the country.

Zoovet has five manufacturing sites located in the city of Santa Fe and a processing plant located in Buenos Aires, all certified with GMP standards by SENASA.

Zoovet is present in more than 30 countries on 4 continents. Its products are available in countries in America, Africa, Asia and Europe. 595 products are registered abroad, 74 in the registration process and 85 under development.

Today ZOOVET has a solid work team made up of more than 200 people.

About Biotechnofe:

This company was a merger of a Biotechnology Development Laboratory's research group from the UNL's School of Biological Sciences, Biochemistry and Zoovet S.A. It specializes in biotechnology and its entrepreneurial team is mostly made up of biotechnologists.

Contact presse :

Emilie Barrail, Group Head of external communication – emilie.barrail@ceva.com - +33 7 85 61 81 15.